NewAmsterdam Pharma in the spotlight

Obicetrapib Shows Promising Results in Phase 3 BROOKLYN Trial

NewAmsterdam Pharma ($NAMS) recently announced positive topline data from their Phase 3 BROOKLYN trial, evaluating their drug obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH). The trial achieved its primary endpoint by demonstrating a statistically significant reduction in LDL-C levels at day 84 of 36.3%, and further reduct…